Submitted:
05 December 2023
Posted:
05 December 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Case Report
3. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Acknowledgments
Conflicts of Interest
References
- Jain, A.; Waseem, M. Chest Trauma. [Updated 2022 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
- Veysi, V.T.; Nikolaou, V.S.; Paliobeis, C.; Efstathopoulos, N.; Giannoudis, P.V. Prevalence of chest trauma, associated injuries and mortality: a level I trauma centre experience. Int Orthop. 2009, 33, 1425–33. [Google Scholar] [CrossRef] [PubMed]
- Bein, T.; Reber, A.; Stjernström, H.; Metz, C.; Taeger, K.; Hedenstierna, G. Ventilation-perfusion ratio in patients with acute respiratory insufficiency. Der Anaesthesist. 1996, 45, 337–342. [Google Scholar] [CrossRef] [PubMed]
- Dunham-Snary, K.J.; Wu, D.; Sykes, E.A.; et al. Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. Chest. 2017, 151, 181–192. [Google Scholar] [CrossRef] [PubMed]
- Nagendran, J.; Stewart, K.; Hoskinson, M.; Archer, S.L. An anesthesiologist’s guide to hypoxic pulmonary vasoconstriction: Implications for managing single-lung anesthesia and atelectasis. Current Opinion in Anaesthesiology 2006, 19, 34–43. [Google Scholar] [CrossRef] [PubMed]
- Moudgil, R.; Michelakis, E.D.; Archer, S.L. Hypoxic pulmonary vasoconstriction. Journal of Applied Physiology 2005, 98, 390–403. [Google Scholar] [CrossRef] [PubMed]
- Gierhardt, M.; Pak, O.; Walmrath, D.; et al. Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. European respiratory review: an official journal of the European Respiratory Society 2021, 30. [Google Scholar] [CrossRef] [PubMed]
- Aston, S.J. Pneumonia in the developing world: Characteristic features and approach to management. Respirology (Carlton, Vic) 2017, 22, 1276–1287. [Google Scholar] [CrossRef] [PubMed]
- Imoto, W.; Yamada, K.; Kuwabara, G.; et al. In which cases of pneumonia should we consider treatments for Stenotrophomonas maltophilia? The Journal of hospital infection 2021, 111, 169–175. [Google Scholar] [CrossRef] [PubMed]
- Shah, M.D.; Coe, K.E.; el Boghdadly, Z.; et al. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. The Journal of antimicrobial chemotherapy 2019, 74, 2055–2059. [Google Scholar] [CrossRef] [PubMed]
- Nicodemo, A.C.; Paez, J.I.G. Antimicrobial therapy for Stenotrophomonas maltophilia infections. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 2007, 26, 229–237. [Google Scholar] [CrossRef]
- Cooper, C.B.; Celli, B. Venous admixture in COPD: pathophysiology and therapeutic approaches. COPD. 2008;5(6):376-381. [CrossRef]
- Yi, H.; Li, X.; Mao, Z. Higher PEEP versus lower PEEP strategies for patients in ICU without acute respiratory distress syndrome: A systematic review and meta-analysis. J Crit Care 2021, 67, 72–78. Epub ahead of print. [CrossRef] [PubMed]
- Rajdev, K.; Spanel, A.J.; McMillan, S. Pulmonary Barotrauma in COVID-19 Patients With ARDS on Invasive and Non-Invasive Positive Pressure Ventilation. J Intensive Care Med. 2021 Sep;36, 1013-1017. Epub 2021 May 20. [CrossRef] [PubMed]
- Shin, T.R.; Oh, Y.M.; Park, J.H.; et al. The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease. J Korean Med Sci. 2015 Oct;30, 1459-65. Epub 2015 Sep 12. PMID: 26425043; PMCID: PMC4575935. [CrossRef]
- Maraolo, A.E.; Licciardi, F.; Gentile, I.; Saracino, A.; Belati, A.; Bavaro, D.F. Stenotrophomonas maltophilia Infections: A Systematic Review and Meta-Analysis of Comparative Efficacy of Available Treatments, with Critical Assessment of Novel Therapeutic Options. Antibiotics (Basel) 2023, 12, 910. [Google Scholar] [CrossRef] [PubMed]




| Parameter | Unit | Predicted | Best | %(Best/Predicted) |
|---|---|---|---|---|
| DLCO_SB | mmol(min*kPa) | 9.25 | 5.50 | 59 |
| KCO_SB | mmol(min*kPa*L) | 1.44 | 1.20 | 83 |
| VA_SB | L | 6.27 | 4.6 | 73 |
| Hemoglobin | g/dL | 14.6 | ||
| DLCOcSB | mmol(min*kPa) | 9.25 | 5.5 | 59 |
| KCOc_SB | mmol(min*kPa*L) | 1.44 | 1.2 | 83 |
| BHT | sec | 11.00 | ||
| VIN_SB | L | 4.17 | 2.5 | 60 |
| TLC_SB | L | 6.42 | 4.72 | 73 |
| FRC_SB | L | 3.34 | 2.93 | 88 |
| ERV_SB | L | 2.15 | 2.23 | 104 |
| RV%TLC_SB | % | 35 | 47 | 136 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).